M&A and equity raisings

6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds

US deals dated after 30 September 2026 are still being collected.

Deal size
Custom range

45 deals · US$6.8bndisclosed · Pharma Services · Clear

Columns
M&A deals and equity raisings
Date Target Vendor Acquirer Type Status Value US$m Sector Advisers
Sep 2026 Lifecore Biomedical –Webster Equity PartnersAcquisitionAnnounced663.7Pharma Services+2 Bourne Capital Partners (sell-side)Craig-Hallum (sell-side)Ballard Spahr (sell-side)Zukerman Gore Brandeis & Crossman (sell-side)Morgan Stanley (buy-side)Goodwin (buy-side)
Sep 2026 MLM Medical Labs –LabcorpAcquisitionAnnounced–Clinical Trial Services+1 William BlairEvercore (buy-side)Pierson Ferdinand (buy-side)Hogan Lovells Cadwalader (buy-side)
Sep 2026 New Zealand Clinical Research Group (NZCR) –AdventAcquisitionAnnounced–Clinical Trial Services Cameron Partners (buy-side)
Sep 2026 portfolio of 20 mature medicines and three manufacturing sites SanofiCheplapharmAsset saleAnnounced–Pharma+1 Freshfields (sell-side)Latham & Watkins (buy-side)
Sep 2026 Ambit RD –Danforth HealthAcquisitionAnnounced–Pharma Services+1 Clearsight Advisors (sell-side)
Sep 2026 Firma Data Services Firma Clinical ResearchEverest Clinical ResearchAsset saleCompleted–Clinical Trial Services+1 Edgemont Partners (sell-side)
Sep 2026 Cellipont Bioservices ––MergerCompleted–Pharma Services+2 William Blair
Sep 2026 Prolytix EdgewaterVIONAcquisitionAnnounced–Pharma Services+1 Stout (sell-side)
Aug 2026 Precision Medicine Group BlackstoneMcKessonAcquisitionAnnounced2,250.0Clinical Trial Services+1 Debevoise & Plimpton (sell-side)Centerview Partners (sell-side)Davis Polk (buy-side)
Aug 2026 ZEPHYRx –a Leading Global CROAcquisitionCompleted–Healthcare Software+1 Morgan Lewis (sell-side)Edgemont Partners (sell-side)
Aug 2026 MAIN5 –AstrixAcquisitionAnnounced–Pharma Services+1 Gibson Dunn (buy-side)
Aug 2026 assets, business operations and customer relationships –NueCell BioAsset saleAnnounced–Pharma Services+1 Goodwin (buy-side)
Aug 2026 Relevate Health Mountaingate Capital–AcquisitionCompleted–Pharma Services+2 Latham & Watkins (sell-side)
Jul 2026 PolyPeptide Group AG –Samsung Biologics Co.AcquisitionAnnounced1,454.0Pharma Services+2 J.P. Morgan (buy-side)EY (buy-side)O'Melveny & Myers (buy-side)Schellenberg Wittmer (buy-side)
Jul 2026 PANTHERx Rare Nautic PartnersWarburg Pincus-led investor groupAcquisitionAnnounced–Healthcare Services+2 Centerview Partners (sell-side)Goldman Sachs (sell-side)Ropes & Gray (sell-side)J.P. Morgan (buy-side)Cleary Gottlieb Steen & Hamilton (buy-side)
Jul 2026 Lannett –AurobindoAcquisitionCompleted250.0Pharma+1 Raymond JamesSullivan & Cromwell (buy-side)
Jul 2026 Gerresheimer global Primary Packaging Plastics business Gerresheimer AGApax PartnersAsset saleAnnounced1,740.5Packaging+2 Latham & Watkins (sell-side)Sullivan & Cromwell (buy-side)
Jul 2026 InfoRLife SA Sergio DusciBC PartnersStakeAnnounced–Pharma Services+1 Latham & Watkins (buy-side)
Jul 2026 Commissioning Agents –JLL PartnersAcquisitionCompleted–Pharma Services+1 Stout (sell-side)
Jul 2026 OptiMed Health Partners –Lee Equity PartnersStakeCompleted–Pharma Services+1 Edgemont Partners (sell-side)
Jul 2026 Asembia –Peak Rock CapitalAcquisitionCompleted–Pharma Services+2 BofA Securities (sell-side)McDermott Will & Schulte (sell-side)Kirkland & Ellis (buy-side)Houlihan Lokey (buy-side)Bass, Berry & Sims (buy-side)
Jun 2026 Simbec-Orion CBPE–MergerAnnounced–Pharma Services+1 Sidley AustinEdgemont Partners
May 2026 AmbioPharm –CordenPharmaAcquisitionAnnounced–Pharma Services+2 Kirkland & EllisBNP Paribas (sell-side)Latham & Watkins (buy-side)
May 2026 MacroGenics GMP manufacturing site and CDMO operations MacroGenicsBora Pharmaceuticals Co.Asset saleCompleted122.5Pharmaceutical Manufacturing+1 Moelis & Company (sell-side)Sidley Austin (sell-side)Covington & Burling (sell-side)Jones Day (buy-side)
May 2026 CDMO and Cell Solutions businesses of Charles River Laboratories Charles River Laboratories InternationalGI PartnersAsset saleCompleted–Pharma Services+2 Moelis & Company (buy-side)Ropes & Gray (buy-side)
Apr 2026 Certara Regulatory and Medical Writing business CertaraVeristatAsset saleAnnounced135.0Pharma Services+1 Perella Weinberg Partners (sell-side)Troutman Pepper Locke (sell-side)Guggenheim Securities (buy-side)McDermott Will & Schulte (buy-side)
Apr 2026 EpiVax –SV Health InvestorsAcquisitionAnnounced–Pharma Services+2 Morgan Lewis (buy-side)
Apr 2026 Accessus Health shareholders of Ecker + Ecker and Accessus HealthAthagorasAcquisitionAnnounced–Accounting, legal and consulting+2 Latham & Watkins (sell-side)
Apr 2026 Modersys (fka SmartFactory Rx) Applied MaterialsTELEO CapitalAsset saleCompleted–Industrial Software+1 Lazard
Apr 2026 Celerion H.I.G. Capital affiliateTHL PartnersAcquisitionAnnounced–Pharma Services+2 LazardKirkland & Ellis (buy-side)Paul, Weiss (buy-side)
Mar 2026 Syntegon CVC Capital PartnersApolloStakeAnnounced–Manufacturing+2 Willkie Farr & Gallagher (sell-side)Sidley Austin (buy-side)
Mar 2026 Owen Mumford Holdings –Embecta Corp.AcquisitionPending132.2Medtech+1 Forvis Mazars (South Africa) (sell-side)Mills & Reeve (sell-side)J.P. Morgan (buy-side)A&O Shearman (buy-side)
Mar 2026 UK Biocentre –Azenta UKAcquisitionCompleted26.9Life Sciences+1 Deloitte (buy-side)Bird & Bird (buy-side)
Mar 2026 Lonza Capsules & Health Ingredients division Lonza Group AGLone Star FundsAsset saleAnnounced–Pharmaceutical Manufacturing+2 Kirkland & Ellis (buy-side)
Mar 2026 Manufacturing facility in Phoenix, AZ Bristol Myers SquibbRoviAsset saleCompleted–Pharmaceutical Manufacturing+1 William Blair
Feb 2026 Laysan Bio –Gannet BioChemAcquisitionAnnounced–Pharma Services+2 Goodwin (buy-side)
Feb 2026 Broth –Supreme GroupAcquisitionAnnounced–Advertising and marketing+1 Edgemont Partners (sell-side)
Jan 2026 SubjectWell ––MergerAnnounced–Clinical Trial Services Stout (sell-side)Fairmount Partners (buy-side)
Jan 2026 Hayden Consulting Group –BGB GroupAcquisitionCompleted–Pharma Services+2 Morgan Lewis (sell-side)Clearsight Advisors (sell-side)
Jan 2026 Nivagen Pharmaceuticals –PAI PharmaAcquisitionAnnounced–Pharmaceutical Manufacturing+1 Bourne Partners (buy-side)Kirkland & Ellis (buy-side)KPMG (buy-side)
Jan 2026 Evidinno Outcomes Research –United BioSourceAcquisitionCompleted–Pharma Services+2 Fairmount Partners (sell-side)
2026 Istituto Biochimico Italiano Giovanni Lorenzini (IBI Lorenzini) –ACS DobfarAcquisitionAnnounced–Pharmaceutical Manufacturing+1 Lincoln International (sell-side)
Nov 2025 Momentum Clinical Research ––MergerCompleted–Clinical Trial Services+1 Harmos Horton Lusk
Sep 2025 Zentiva Advent InternationalGTCRAcquisitionAnnounced–Pharma+1 Goldman Sachs (sell-side)PJT Partners (sell-side)Freshfields (sell-side)Barclays (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side)
Jun 2025 Felix Pharmaceuticals Pvt –Advent InternationalStakeAnnounced–Animal Health+2 A&L Goodbody LLPLincoln International (sell-side)Guggenheim Securities (buy-side)

Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.